Article
Advances in Development of New Treatment for Leishmaniasis.
Registro en:
MENEZES, J. P. B et al. Advances in Development of New Treatment for Leishmaniasis. BioMed Research International, 815023, 2015.
2314-6141
dx.doi.org/10.1155/2015/815023
Autor
Menezes, Juliana Perrone Bezerra de
Guedes, Carlos Eduardo Sampaio
Petersen, Antonio Luis de Oliveira Almeida
Fraga, Deborah Bittencourt Mothé
Veras, Patrícia Sampaio Tavares
Resumen
Leishmaniasis is a neglected infectious disease caused by several different species of protozoan parasites of the genus Leishmania.
Current strategies to control this disease are mainly based on chemotherapy.Despite being available for the last 70 years, leishmanial
chemotherapy has lack of efficiency, since its route of administration is difficult and it can cause serious side effects, which results
in the emergence of resistant cases.The medical-scientific community is facing difficulties to overcome these problems with new
suitable and efficient drugs, as well as the identification of new drug targets. The availability of the complete genome sequence of
Leishmania has given the scientific community the possibility of large-scale analysis, which may lead to better understanding of
parasite biology and consequent identification of novel drug targets. In this review we focus on how high-throughput analysis is
helping us and other groups to identify novel targets for chemotherapeutic interventions.We further discuss recent data produced
by our group regarding the use of the high-throughput techniques and how this helped us to identify and assess the potential of
new identified targets.